A phase 2, single-blind, randomized, controlled, multi-center study to evaluate the efficacy and safety of SRM003 (Vascugel) in improving the rate of arteriovenous fistula maturation and use in subjects undergoing surgery for creation of an arteriovenous fistula for hemodialysis access
Phase of Trial: Phase II
Latest Information Update: 08 Jan 2016
Price : $35 *
At a glance
- Drugs SRM 003 (Primary)
- Indications Arteriovenous fistula
- Focus Therapeutic Use
- Sponsors Shire
- 04 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Sep 2014 Planned End Date changed from 1 Dec 2014 to 1 Apr 2015, as reported by ClinicalTrials.gov
- 18 Jul 2014 According to a Shire Pharmaceuticals media release, no new patients will be enrolled in this and another phase II trial (700237715), but those currently in the trials will be followed for at least 12 weeks for safety.